Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605189 | 0.96 | MMP13 (0.60) | MMP13MAPTKMT2AL3MBTL1THRB | |
| SCHEMBL6512902 | 0.90 | ALDH1A1 (0.53) | MAPTKMT2AHPGDDRD2GAA | |
| SCHEMBL6604906 | 0.87 | L3MBTL1 (0.50) | MMP13L3MBTL1THRBLMNATDP1 | |
| SCHEMBL6606492 | 0.86 | LMNA (0.52) | MMP13MAPTTHRBLMNADRD2 | |
| SCHEMBL6609494 | 0.85 | LMNA (0.51) | MMP13MAPTKMT2ATHRBLMNA | |
| SCHEMBL6605355 | 0.84 | LMNA (0.51) | MMP13MAPTTHRBLMNADRD2 | |
| SCHEMBL6517676 | 0.83 | MAPT (0.44) | MAPTKMT2ALMNA | |
| SCHEMBL6609773 | 0.82 | ALDH1A1 (0.44) | MAPTKMT2ATHRBLMNADRD2 | |
| SCHEMBL6606914 | 0.82 | ALDH1A1 (0.49) | MAPTDRD2GAA | |
| SCHEMBL6470694 | 0.81 | NPC1 (0.51) | MMP13MAPTKMT2ATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368327-B1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1368327-B1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-6656932-B2 | Treating osteoarthritis, rheumatoid arthritis, cancer, inflammation, and heart failure | WARNER-LAMBERT COMPANY | 2003-12-02 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | MMP13 2/4885MAPT 4336/4885KMT2A 1627/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | MMP13 1/4885MAPT 1774/4885KMT2A 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.